News

BACKGROUND: Fontan circulatory failure (FCF) is a chronic state in palliated single ventricle heart disease with high morbidity and mortality rates, including heart failure, multisystem end-organ ...
BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...
Cardiovascular disease (CVD) mortality increased by 78%, rising from 72.4 to 128.7 per 100 000 (2017–2022), with the greatest ...
Early reports of incident myocardial injury during the COVID-19 pandemic hastened an update in the diagnostic approach to myocarditis, taking advantage of progress in imaging and biomarker analytic ...
Using the Global Burden of Disease 2021 data, we analyzed the prevalence and disability‐adjusted life years, examining implications across demographics and geographic regions. In 2021, an estimated 54 ...
Circulation: Arrhythmia and Electrophysiology A specialized journal dedicated to advancing the understanding and management of cardiac arrhythmias and electrophysiology Editor-in-Chief: Paul J. Wang, ...
BACKGROUND: Evaluation of whether dyspnea has a cardiac cause is essential. Guidelines from 2016 were reported to result in a ...
Although heart transplantation is the preferred therapy for appropriate patients with advanced heart failure, the presence of concomitant renal or hepatic dysfunction can pose a barrier to isolated ...
The expression and function of NPRC in DKD were investigated using human renal biopsies and a diabetic mouse model. Podocyte-specific NPRC knockout mice were developed to explore the role of NPRC in ...
Cardiovascular disease (CVD) is the predominant cause of death globally, accounting for ≈30% of deaths each year. 1 The prevalence of CVD among adults (aged ≥20 years) in the United States was 48.6% ...
Abstract—We studied the long-term effects of vitamins E and C and their combination on lipid peroxidation in vivo and in vitro. The Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) ...
Open in Viewer Figure. Ruxolitinib treatment in AFM: clinical timeline and molecular and cellular responses. A, Clinical timeline illustrating ruxolitinib and methylprednisolone administration, ...